Avi Cherla

Avi Cherla

PhD student

Department of Health Policy

Connect with me

Key Expertise
Pharmaceutical Economics and Policy, Clinical Trials

About me

Avi is a Senior Health Policy Associate with LSE Health and a PhD candidate in the Department of Health Policy at LSE. While working at LSE Health, he has consulted for Ministries of Health and international organisations on several topics including high-cost medicines, low-value care, and cardiovascular disease.

Avi’s published research has focused on the evidence of new drugs in the United States and Europe. His PhD investigates uncertainty associated with the clinical trial evidence supporting new cancer drugs in the US and the implications this has for regulatory decision making, insurance coverage, and patient choices. Prior to joining the department, Avi earned an MSc from the London School of Economics and Political Science and the London School of Hygiene and Tropical Medicine.


Dissertation title:

Uncertainty associated with clinical evidence supporting new cancer drugs


Dissertation supervisors:

Dr Huseyin Naci, Professor Elias Mossialos, Dr Olivier Wouters 



  • Jenei K, Raymakers AJN, Bayle A, Berger-Thurmel K, Cherla A, Honda K, Jackson CCGA, Karikos D, Trapani D, Berry S, Gyawali B. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. Lancet Oncol. 2023;24(6):624-635. doi: 10.1016/S1470-2045(23)00175-4.
  •  Cherla A, Mossialos E, Salcher-Konrad M, Kesselheim AS, Naci H. Post-marketing requirements for cancer drugs approved by the European Medicines Agency, 2004-2014. Clin Pharmacol Ther. 2022;112(4): 846-852. doi;10.1002/cpt.2679
  •        Cherla A, Naci H, Kesselheim AS, Gyawali B, Mossialos E. Assessment of coverage in England of cancer drugs qualifying for US Food and Drug Administration accelerated approval. JAMA Intern Med. 2021;181(4):490-498. doi:10.1001/jamainternmed.2020.8441
  •        Cherla A, Renwick M, Jha A, Mossialos E. Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England. EClinicalMedicine. 2020;29-30:100625. doi:10.1016/j.eclinm.2020.100625
  •        Cherla A, Renwick M, Stefanini G, Holmes DR, Mossialos E. Cost-effectiveness of cardiovascular, obesity, and diabetes mellitus drugs: Comparative analysis of the United States and England. J Am Heart Assoc. 2020;9(21):e018281. doi:10.1161/JAHA.120.018281
  •        Cherla A, Howard N, Mossialos E. The “Netflix plus model”: Can subscription financing improving access to medicines in low- and middle-income countries? Health Econ Policy Law. 2020;16(2):113-123. doi:10.1017/S1744133120000031